Anika Therapeutics Inc (ANIK) 13F Holders & Ownership Data (135 Funds, Q2 2026)

ANIK ranks #3932 out of 37503 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

135 institutions disclose a position in ANIK, but none treat it as a major bet — even Caligan Partners LP, its most concentrated holder, allocates just 1.0% of its own portfolio to it.

Cliff Asness has added to its ANIK position for two straight quarters, increasing it by $7.5M to reach $8.2M today.

Trexquant Investment LP has trimmed its ANIK position for two straight quarters, cutting it by $579.3K while still holding $451.9K.

ANIK is up 2.1% today, and institutions have been net buyers of $3.7M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

ANIK reported a net loss of $3.8M over the trailing twelve months.

• Not yet profitable — net loss of $3.8M over the trailing twelve months
• Revenue grew 46.0% year over year
• Net income improved year over year, from -$60.6M to -$3.8M
• Generated $11.2M in positive operating cash flow
• Current ratio of 4.72x — enough short-term assets to cover short-term liabilities
• Liabilities run 1.33x equity — within a conventional range